Abstract ID: LBA1004 A randomized phase II trial of fulvestrant or exemestane with or without Ribociclib after progression on Anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone recep
讲者：郝春芳
单位：天津肿瘤医院
Abstract ID: 1005 Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive breast cancer (FAKTION): Overall survival and updated progression free surviva
专家评述
讲者：王晓稼
单位：浙江省肿瘤医院
Abstract ID: LBA3 Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04 , a randomized, phase 3 study
讲者：王涛
单位：解放军总医院
Abstract ID: LBA1001 Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (Pts) With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer.
Abstract ID: LBA5500 ATHENA-MONO: A randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment following response to frontline platinum-based chemotherapy in ovarian cancer
讲者：李宁
单位：中国医学科学院肿瘤医院
讲者：王树森
单位：中山大学附属肿瘤医院
Abstract ID: 5502 Bevacizumab in first-line chemotherapy to improve the survival outcome for advanced ovarian clear cell carcinoma: A multicenter, retrospective analysis.
Abstract ID: 5509 Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
讲者：袁光文
讲者：杨宏英
单位：云南省肿瘤医院
